Skip to main navigation
  • Home
    • Company
    • Need for Abuse Deterrent Products
    • Platforms
  • Technologies
    • Technology Platforms
    • AVERSION®
    • IMPEDE®
    • LIMITX™
  • Market Opportunity
    • Market Opportunity
    • Partnerships
    • Advocacy Groups
    • Patents
    • Business Development
  • Product Portfolio
    • Product Pipeline
    • OXAYDO®
    • NEXAFED® Product Line
    • LIMITX™ Products in Development
    • Important Safety Info
  • Clinical
    • Medical Meeting Calendar
  • Investors

    Investors

    • Investors
    • Press Releases
    • News & Events
    • Corporate Governance
      • Management
      • Directors
      • Committees
      • ContactBoard
    • Financial Information
      • SEC Filings
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Ownership Profile
    • Risk Factors
    • Contact Us
 

acura

Contact Us
 
Share this on: Close window
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter

Investor Relations

  • Investors
  • Press Releases
  • News & Events
  • Corporate Governance
  • Financial Information
  • Stock Information
  • Risk Factors
  • Contact Us

Shareholder Tools

  • Email Alerts
  • Downloads
  • RSS News
  • Print Page
  • Share This

Press Releases

Company News
Summary ToggleAcura Pharmaceuticals, Inc. Announces Notice Of Allowance For Third Aversion® Technology Patent
Jun 06, 2011

Read more

Summary Toggle Acura Pharmaceuticals, Inc. Announces Appointment Of Robert Jones As Interim President & CEO
May 02, 2011

Read more

Summary Toggle Acura Pharmaceuticals, Inc. Announces The Passing Of Andrew Reddick, President & CEO
Apr 29, 2011

Read more

Summary Toggle Acura Pharmaceuticals Reports First Quarter 2011 Financial Results And Product Development Update
Apr 28, 2011

Read more

Summary Toggle Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave
Apr 25, 2011

Read more

Summary ToggleAcura Pharmaceuticals Reports Year-End And Fourth Quarter 2010 Financial Results And Product Development Update
Mar 01, 2011

Read more

Summary ToggleACUROX® Tablets New Drug Application Accepted For Filing With A Priority Review Classification
Feb 14, 2011

Read more

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
Displaying 145 - 151 of 151 results

Copyright © 1998-2021 Acura Pharmaceuticals. All rights reserved. Terms of Use and Privacy Policy Risk Factors Contact Us